CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference

MONMOUTH JUNCTION, N.J., Feb. 5, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present at the 21st Annual BIO CEO & Investor Conference next week in New York City.

CytoSorbents Logo. (PRNewsFoto/CytoSorbents)

21st Annual BIO CEO & Investor Conference

Where:

New York Marriott Marquis, 1535 Broadway, New York, NY 10036

When:

Monday, February 11, 2019 at 2:00PM ET

Room:

Chelsea Room

Webcast:

http://www.veracast.com/webcasts/bio/ceoinvestor2019/12120406671.cfm

Conference Website:

2019 BIO CEO and Investor Conference

Dr. Chan stated, "CytoSorb is approved in the European Union with distribution in 55 countries worldwide, and has been used in more than 56,000 human treatments to help control deadly inflammation in a wide variety of life-threatening inflammatory conditions such as sepsis and infection, influenza, trauma, liver failure, lung injury, cytokine release syndrome in cancer immunotherapy, and complications of surgery.  Sales of CytoSorb grew by approximately 50% in 2018 to more than $20 million, with healthy blended product gross margins of 72%."

"We believe we are in the early stages of what could be a significant multi-year growth story, with a biotech-sized opportunity and the lower risk profile of a medical device company with rapidly growing sales and high gross margins."

Currently, the management team will be available on February 11-12th for one-on-one meetings with investors.  To schedule a meeting, please use the BIO CEO One-on-One meeting portal for registered participants.  An archived version of the webcast will be available 1 hour after the presentation.

About BIO and the BIO CEO & Investor Conference

BIO, the Biotechnology Innovation Organization, is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

The 21st Annual BIO CEO & Investor Conference is one of the largest investor conferences that assemble a select group of established biotech companies, as well as top public and private equity investors and members of the sell-side investment community, to explore the current investment landscape and opportunities in life sciences.  In addition to plenary sessions and panel discussions on timely business topics and key therapeutic areas, the conference features presentations and one-on-one meetings with over 150 leading biotechnology and pharmaceutical companies, as well as a number of nonprofit and venture philanthropy organizations. 

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution  in 55 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist.  CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorbents is conducting its pivotal REFRESH 2-AKI trial – a multi-center, randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex cardiac surgery to reduce organ injury.  CytoSorb® has been used in more than 56,000 human treatments to date.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of nearly $26 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (USSOCOM), and others. The Company has numerous products under development based upon this unique patented blood purification technology including CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others.  For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com and follow us on Facebook and Twitter

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 8, 2018, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. 

Please Click to Follow Us on Facebook and Twitter

Cytosorbents Contact:

Amy Vogel

Investor Relations

732-398-5394

avogel@cytosorbents.com

 

Investor Relations Contact:

Jeremy Feffer

LifeSci Advisors

917-749-1494

jeremy@lifesciadvisors.com

 

Public Relations Contact:

Joshua Berkman

Rubenstein Public Relations

212-805-3055

jberkman@rubensteinpr.com

 

SOURCE CytoSorbents Corporation


print email rss